AndzonBio2 and University of Cambridge Partner on Neuroinflammation Therapeutics

AndzonBio2 has entered into agreements with the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise to develop therapeutics aimed at neuroinflammation, announced in a press release. The collaboration focuses on creating first in class treatments for conditions such as Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis.

The partners will combine AndzonBio2's expertise in early drug development with Cambridge's neuroscience research and the institute's drug discovery platform. Their joint program will target biological pathways involved in neuroinflammatory processes.

Under the agreement, AndzonBio2 receives an exclusive option to license resulting intellectual property and advance the program through preclinical and clinical stages. The partnership is designed to integrate academic research with industrial development to accelerate progress toward candidate selection and future trials.

The collaboration aligns with Cambridge's mission to translate neuroscience discoveries into potential therapies through partnerships with industry experts.